alprostadil · Pfizer · NDA 020379, 020755
Caverject
Earliest generic entry, as listed · earliest of 3 marketed strengths
Open now
No unexpired patents or exclusivities are listed for this product.
Listed patents · 0 unexpired
No unexpired patents listed.
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 7
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 020379 · 001 · RLD | injectable, injection | 0.01MG/VIAL | open |
| 020379 · 002 · RLD | injectable, injection | 0.02MG/VIAL | open |
| 020379 · 003 · RLD · discontinued | injectable, injection | 0.005MG/VIAL | open |
| 020379 · 004 · RLD | injectable, injection | 0.04MG/VIAL | open |
| 020755 · 001 · discontinued | injectable, injection | 0.005MG/ML | open |
| 020755 · 002 · discontinued | injectable, injection | 0.01MG/ML | open |
| 020755 · 003 · discontinued | injectable, injection | 0.02MG/ML | open |